J&J faces Stelara losses, Medicare shifts, talc suits and China pressure, banking on new products and expects segment growth ...

Medicare’s 2026 drug price negotiations under the Inflation Reduction Act aim to lower the cost of expensive medications, ...

The new rule is expected to extend the telemedicine flexibilities through the end of 2026 and will maintain the status quo while the DEA and the Department of Health and Human Services work toward a ...

Below is Alston & Bird’s Health Care Week in Review, which provides a synopsis of the latest news in health care regulations, notices, and ...

Discover how new U.S. Medicare drug price cuts impact major pharma stocks like Novo Nordisk and why sector resilience ...

CMS announces billions in savings for Medicare when first and second rounds of negotiations go into effect in 2026 and 2027, ...

The trial proved so successful that Bayer plans to reach out to regulators in preparation for submitting the drug candidate ...

Bayer's asundexian hits key goals in the OCEANIC-STROKE study, showing reduced ischemic stroke risk without added major bleeding.

Findings are respite for German conglomerate facing sliding sales of blockbuster drugs and US legal challenges ...

The pharma company said asundexian, when combined with antiplatelet therapy, lowered the risk of stroke in patients during the study.

Every year, people around the world take an astonishing 3.8 trillion doses of medicine. Most of these medicines are swallowed rather than injected or inhaled, because the oral route is the easiest, ...

Ms. Szalavitz is a contributing Opinion writer who covers addiction and public policy. Recently, I snapped at my best friend for being 10 minutes late — atypical behavior for me. I hadn’t realized how ...